Aptamers: Novel molecules as diagnostic markers in bacterial and viral infections?

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Zimbres, Flávia M ^a   Tárnok, Attila ^b   Ulrich, Henning ^a   Wrenger, Carsten ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; BIOLOGICAL MARKER; LIGAND; DIAGNOSTIC AGENT;

BACTERIAL INFECTION; EVOLUTION; HUMAN; NONHUMAN; PATHOGENESIS; REVIEW; VIRUS INFECTION; ANIMAL; BACTERIAL INFECTIONS; CHEMISTRY; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE; VIRUS DISEASES; COMBINATORIAL CHEMISTRY;

ANIMALS; APTAMERS, NUCLEOTIDE; BACTERIAL INFECTIONS; BIOMARKERS; HUMANS; SELEX APTAMER TECHNIQUE; VIRUS DISEASES; BIOLOGICAL MARKERS;

EID: 84884883255     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/731516     Document Type: Review

References (60)

1. Shi G., Yagyu F., Shimizu Y., Shimizu K., Oshima M., Iwamoto A., Gao B., Liu W., Gao G. F., Kitamura Y., Flow cytometric assay using two fluorescent proteins for the function of the internal ribosome entry site of hepatitis C virus. Cytometry Part A 2011 79 8 653 660 2-s2.0-79960560296 10.1002/cyto.a.21094
2. Gondois-Rey F., Granjeaud S., Kieu S. L. T., Herrera D., Hirsch I., Olive D., Multiparametric cytometry for exploration of complex cellular dynamics. Cytometry Part A 2012 81 4 332 342 2-s2.0-84858762461 10.1002/cyto.a.22016
3. Pollara J., Hart L., Brewer F., Pickeral J., Packard B. Z., Hoxie J. A., Komoriya A., Ochsenbauer C., Kappes J. C., Roederer M., Huang Y., Weinhold K. J., Tomaras G. D., Haynes B. F., Montefiori D. C., Ferrari G., High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry Part A 2011 79 8 603 612 2-s2.0-79960555557 10.1002/cyto.a.21084
4. Mateos-Pérez J. M., Redondo R., Nava R., Valdiviezo J. C., Cristóbal G., Escalante-Ramírez B., Ruiz-Serrano M. J., Pascau J., Desco M., Comparative evaluation of autofocus algorithms for a real-time system for automatic detection of Mycobacterium tuberculosis. Cytometry Part A 2012 81 3 213 221 2-s2.0-84857374531 10.1002/cyto.a.22020
5. Ruger M., Bensch G., Tungler R., Reichl U., A flow cytometric method for viability assessment of Staphylococcus aureus and Burkholderia cepacia in mixed culture. Cytometry Part A 2012 81 1055 1066
6. Ellington A. D., Szostak J. W., In vitro selection of RNA molecules that bind specific ligands. Nature 1990 346 6287 818 822 2-s2.0-0025074907 10.1038/346818a0 (Pubitemid 20272100)
7. Tuerk C., Gold L., Systemic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990 249 4968 505 510 2-s2.0-0025194307
8. Ulrich H., Martins A. H. B., Pesquero J. B., RNA and DNA aptamers in cytomics analysis. Current Protocols in Cytometry 2005 7 1 39 2-s2.0-53249123429
9. Ulrich H., Martins A. H. B., Pesquero J. B., RNA and DNA aptamers in cytomics analysis. Cytometry Part A 2004 59 2 220 231 2-s2.0-2942598177 (Pubitemid 38736297)
10. Harada K., Frankel A. D., Identification of two novel arginine binding DNAs. The EMBO Journal 1995 14 23 5798 5811 2-s2.0-0028823341
11. Davydova A. S., Vorobjeva M. A., Venyaminova A. G., Escort aptamers: new tools for the targeted delivery of therapeutics into cells. Acta Naturae 2011 3 12 29
12. Ng E. W. M., Shima D. T., Calias P., Cunningham E. T. Jr., Guyer D. R., Adamis A. P., Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nature Reviews Drug Discovery 2006 5 2 123 132 2-s2.0-33645095226 10.1038/nrd1955
13. Nery A. A., Wrenger C., Ulrich H., Recognition of biomarkers and cell-specific molecular signatures: aptamers as capture agents. Journal of Separation Science 2009 32 10 1523 1530 2-s2.0-67649979546 10.1002/jssc. 200800695
14. Murphy M. B., Fuller S. T., Richardson P. M., Doyle S. A., An improved method for the in vitro evolution of aptamers and applications in protein detection and purification. Nucleic Acids Research 2003 31 18 e110 2-s2.0-1042296535
15. Rybak J.-N., Scheurer S. B., Neri D., Elia G., Purification of biotinylated proteins on streptavidin resin: a protocol for quantitative elution. Proteomics 2004 4 8 2296 2299 2-s2.0-3543072968 10.1002/pmic.200300780 (Pubitemid 39025329)
16. Ulrich H., Wrenger C., Disease-specific biomarker discovery by aptamers. Cytometry Part A 2009 75 9 727 733 2-s2.0-68849108343 10.1002/cyto.a.20766
17. Famulok M., Mayer G., Blind M., Nucleic acid aptamers-from selection in vitro to applications in vivo. Accounts of Chemical Research 2000 33 9 591 599 2-s2.0-0033797244 10.1021/ar960167q
18. Tombelli S., Minunni M., Mascini M., Analytical applications of aptamers. Biosensors and Bioelectronics 2005 20 12 2424 2434 2-s2.0-18044372281 10.1016/j.bios.2004.11.006 (Pubitemid 40602182)
19. Conrad R., Ellington A. D., Detecting immobilized protein kinase C isozymes with RNA aptamers. Analytical Biochemistry 1996 242 2 261 265 2-s2.0-0030589094 10.1006/abio.1996.0462 (Pubitemid 26386823)
20. Sekiya S., Nishikawa F., Noda K., Kumar P. K., Yokoyama T., Nishikawa S., In vitro selection of RNA aptamers against cellular and abnormal isoform of mouse prion protein. Nucleic Acids Symposium Series 2005 49 361 362 2-s2.0-33744540198
21. Renslo A. R., McKerrow J. H., Drug discovery and development for neglected parasitic diseases. Nature Chemical Biology 2006 2 12 701 710 2-s2.0-33751080094 10.1038/nchembio837 (Pubitemid 44764212)
22. Bloom B., Fine P., Bloom B. R., The BCG experience: implications for future vaccines against tuberculosis. Tuberculosis: Pathogenesis, Protection and Control 1994 Washington, DC, USA ASM Press 531 557
23. Chen F., Zhou J., Luo F., Mohammed A.-B., Zhang X.-L., Aptamer from whole-bacterium SELEX as new therapeutic reagent against virulent Mycobacterium tuberculosis. Biochemical and Biophysical Research Communications 2007 357 3 743 748 2-s2.0-34247536631 10.1016/j.bbrc.2007.04.007 (Pubitemid 46653843)
24. Chen F., Hu Y., Li D., Chen H., Zhang X.-L., CS-SELEX generates high-affinity ssDNA aptamers as molecular probes for hepatitis C virus envelope glycoprotein E2. PLoS ONE 2009 4 12 2-s2.0-77949503400 10.1371/journal.pone. 0008142 e8142
25. Joshi R., Janagama H., Dwivedi H. P., Senthil Kumar T. M. A., Jaykus L.-A., Schefers J., Sreevatsan S., Selection, characterization, and application of DNA aptamers for the capture and detection of Salmonella enterica serovars. Molecular and Cellular Probes 2009 23 1 20 28 2-s2.0-59049089355 10.1016/j.mcp.2008.10.006
26. Zuker M., Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Research 2003 31 13 3406 3415 2-s2.0-0042121256 10.1093/nar/gkg595 (Pubitemid 37442169)
27. Gupta A., Fontana J., Crowe C., Bolstorff B., Stout A., Van Duyne S., Hoekstra M. P., Whichard J. M., Barrett T. J., Angulo F. J., Emergence of multidrug-resistant Salmonella enterica serotype Newport infections resistant to expanded-spectrum cephalosporins in the United States. Journal of Infectious Diseases 2003 188 11 1707 1716 2-s2.0-0346256761 10.1086/379668 (Pubitemid 38010682)
28. Wells S. J., Fedorka-Cray P. J., Dargatz D. A., Ferris K., Green A., Fecal shedding of Salmonella spp. by dairy cows on farm and at cull cow markets. Journal of Food Protection 2001 64 1 3 11 2-s2.0-0035139297 (Pubitemid 32102886)
29. Malorny B., Hoorfar J., Toward standardization of diagnostic PCR testing of fecal samples: lessons from the detection of salmonellae in pigs. Journal of Clinical Microbiology 2005 43 7 3033 3037 2-s2.0-22144483803 10.1128/JCM.43.7.3033-3037.2005 (Pubitemid 40981298)
30. Carli K. T., Eyigor A., Caner V., Prevalence of Salmonella serovars in chickens in Turkey. Journal of Food Protection 2001 64 11 1832 1835 2-s2.0-0035543236 (Pubitemid 34010106)
31. Nayak R., Kenney P. B., Keswani J., Ritz C., Isolation and characterisation of Salmonella in a turkey production facility. British Poultry Science 2003 44 2 192 202 2-s2.0-0242657288 10.1080/0007166031000088370 (Pubitemid 37399852)
32. Pan Q., Zhang X.-L., Wu H.-Y., He P.-W., Wang F., Zhang M.-S., Hu J.-M., Xia B., Wu J., Aptamers that preferentially bind type IVB pili and inhibit human monocytic-cell invasion by Salmonella enterica serovar typhi. Antimicrobial Agents and Chemotherapy 2005 49 10 4052 4060 2-s2.0-25844501616 10.1128/AAC.49.10.4052-4060.2005 (Pubitemid 41400946)
33. Cao X., Li S., Chen L., Ding H., Xu H., Huang Y., Li J., Liu N., Cao W., Zhu Y., Shen B., Shao N., Combining use of a panel of ssDNA aptamers in the detection of Staphylococcus aureus. Nucleic Acids Research 2009 37 14 4621 4628 2-s2.0-69049105481 10.1093/nar/gkp489
34. Wang R., Zhao J., Jiang T., Selection and characterization of DNA aptamers for use in detection of avian influenza virus H5N1. Journal of Virological Methods 2013 189 362 369 10.1016/j.jviromet.2013.03.006
35. Liang H. R., Liu Q., Zheng X. X., Aptamers targeting rabies virus-infected cells inhibit viral replication both in vitro and in vivo. Virus Research 2013 173 2 398 403 10.1016/j.virusres.2012.12.017
36. + T cell decline in humanized mice. Science Translational Medicine 2011 3 66 2-s2.0-78751667739 10.1126/scitranslmed.3001581 66ra6
37. Fisher T. S., Joshi P., Prasad V. R., Mutations that confer resistance to template-analog inhibitors of human immunodeficiency virus (HIV) type 1 reverse transcriptase lead to severe defects in HIV replication. Journal of Virology 2002 76 8 4068 4072 2-s2.0-0036197059 10.1128/JVI.76.8.4068-4072.2002 (Pubitemid 34250570)
38. Held D. M., Kissel J. D., Saran D., Michalowski D., Burke D. H., Differential susceptibility of HIV-1 reverse transcriptase to inhibition by RNA aptamers in enzymatic reactions monitoring specific steps during genome replication. Journal of Biological Chemistry 2006 281 35 25712 25722 2-s2.0-33748753169 10.1074/jbc.M604460200 (Pubitemid 44401960)
39. Burke D. H., Scates L., Andrews K., Gold L., Bent pseudoknots and novel RNA inhibitors of type 1 human immunodeficiency virus (HIV-1) reverse transcriptase. Journal of Molecular Biology 1996 264 4 650 666 2-s2.0-0030582678 10.1006/jmbi.1996.0667 (Pubitemid 27013551)
40. Joshi P., Prasad V. R., Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment). Journal of Virology 2002 76 13 6545 6557 2-s2.0-0036284226 10.1128/JVI.76.13.6545-6557. 2002 (Pubitemid 34633520)
41. Tuerk C., MacDougal S., Gold L., RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase. Proceedings of the National Academy of Sciences of the United States of America 1992 89 15 6988 6992 2-s2.0-0026651981 10.1073/pnas.89.15.6988
42. Lowy F. D., Medical progress: Staphylococcus aureus infections. The New England Journal of Medicine 1998 339 8 520 532 2-s2.0-0032551901 10.1056/NEJM199808203390806 (Pubitemid 28384886)
43. Qtaishat N. M., Gussin H. A., Pepperberg D. R., Cysteine-terminated B-domain of Staphylococcus aureus protein A as a scaffold for targeting GABA(A) receptors. Analytical Biochemistry 2013 432 49 57
44. Beier D., Gross R., Regulation of bacterial virulence by two-component systems. Current Opinion in Microbiology 2006 9 2 143 152 2-s2.0-33645881935 10.1016/j.mib.2006.01.005
45. Bronner S., Monteil H., Prévost G., Regulation of virulence determinants in Staphylococcus aureus: complexity and applications. FEMS Microbiology Reviews 2004 28 2 183 200 2-s2.0-1942517962 10.1016/j.femsre.2003. 09.003 (Pubitemid 38510501)
46. Loughman A., Sweeney T., Keane F. M., Pietrocola G., Speziale P., Foster T. J., Sequence diversity in the A domain of Staphylococcus aureus fibronectin-binding protein A. BMC Microbiology 2008 8, article 74 2-s2.0-44049084008 10.1186/1471-2180-8-74 (Pubitemid 351713341)
47. van der Woude M. W., Bäumler A. J., Phase and antigenic variation in bacteria. Clinical Microbiology Reviews 2004 17 3 581 611 2-s2.0-3242757523 10.1128/CMR.17.3.581-611.2004 (Pubitemid 38970684)
48. Bellecave P., Moradpour D., A fresh look at interferon-alpha signaling and treatment outcomes in chronic hepatitis C. Hepatology 2008 48 1330 1333
49. Boyer N., Marcellin P., Pathogenesis, diagnosis and management of hepatitis C. Journal of Hepatology 2000 32 1 98 112 2-s2.0-0034092720 (Pubitemid 30123628)
50. Liu C. H., Liu C. J., Lin C. L., Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clinical Infectious Diseases 2008 47 1260 1269 10.1086/592579
51. Sarasin-Filipowicz M., Oakeley E. J., Duong F. H. T., Christen V., Terracciano L., Filipowicz W., Heim M. H., Interferon signaling and treatment outcome in chronic hepatitis C. Proceedings of the National Academy of Sciences of the United States of America 2008 105 19 7034 7039 2-s2.0-44349109098 10.1073/pnas.0707882105 (Pubitemid 351754525)
52. Sullenger B. A., Gallardo H. F., Ungers G. E., Gilboa E., Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 1990 63 3 601 608 2-s2.0-0025188193 10.1016/0092-8674(90) 90455-N (Pubitemid 20374104)
53. Dey A. K., Khati M., Tang M., Wyatt R., Lea S. M., James W., An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction. Journal of Virology 2005 79 21 13806 13810 2-s2.0-27144483814 10.1128/JVI.79.21.13806-13810.2005 (Pubitemid 41508193)
54. Khati M., Schüman M., Ibrahim J., Sattentau Q., Gordon S., James W., Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2 ′ F-RNA aptamers. Journal of Virology 2003 77 23 12692 12698 2-s2.0-0242409220 10.1128/JVI.77.23.12692- 12698.2003 (Pubitemid 37430664)
55. Jaeger J., Restle T., Steitz T. A., The structure of HIV-1 reverse transcriptase complexed with an RNA pseudoknot inhibitor. The EMBO Journal 1998 17 15 4535 4542 2-s2.0-0032480010 10.1093/emboj/17.15.4535 (Pubitemid 28362641)
56. Chaloin L., Lehmann M. J., Sczakiel G., Restle T., Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1. Nucleic Acids Research 2002 30 18 4001 4008 2-s2.0-0037106622
57. Lange M. J., Sharma T. K., Whatley A. S., Robust suppression of HIV replication by intracellularly expressed reverse transcriptase aptamers is independent of ribozyme processing. Molecular Therapy 2012 20 2304 2314 10.1038/mt.2012.158
58. Ulrich H., Wrenger C., Identification of aptamers as specific binders and modulators of cell-surface receptor activity. Methods in Molecular Biology 2013 986 17 39
59. Ferrara N., Gerber H.-P., LeCouter J., The biology of VEGF and its receptors. Nature Medicine 2003 9 6 669 676 2-s2.0-0037699954 10.1038/nm0603-669 (Pubitemid 36749215)
60. Ruckman J., Green L. S., Beeson J., Waugh S., Gillette W. L., Henninger D. D., Claesson-Welsh L., Janjić N., 2 ′ -fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165): inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. Journal of Biological Chemistry 1998 273 32 20556 20567 2-s2.0-0032493654 10.1074/jbc.273.32.20556 (Pubitemid 28377626)